# Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

> **NCT05145062** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sangamo Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Blood and Lymphatic Diseases

## Interventions

- **DRUG:** BIVV003
- **DRUG:** ST-400

## Key facts

- **NCT ID:** NCT05145062
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-21
- **Primary completion:** 2038-07-14
- **Final completion:** 2038-07-14
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145062, "Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05145062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*